Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nautilus Biotechnolgy (NAUT)
NASDAQ:NAUT
RESEARCH TOOLSreports
Nautilus Biotechnolgy (NAUT) Stock Price & Analysis
110 Followers
NAUT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.16 - $4.65
Previous Close$2.46
Volume52.50K
Average Volume (3M)78.14K
Market Cap
$292.73M
Enterprise Value$153.94M
Total Cash (Recent Filing)$173.42M
Total Debt (Recent Filing)$34.63M
Price to Earnings (P/E)-4.8
Beta1.51
Next Earnings
Apr 30, 2024EPS Estimate
-$0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding125,098,080
10 Day Avg. Volume64,958
30 Day Avg. Volume78,138
Standard Deviation0.16
R-Squared0.16
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.10
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.70
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.76
Forecast
1Y Price Target
$3.88Price Target Upside57.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Nautilus Biotechnolgy News
Bulls Say, Bears Say
Bulls Say
Financial ManagementThe company is confident in managing cash burn, with a cash runway expected to last until the second half of 2026.
Financial PerformanceOperating expenses were slightly below consensus estimates, indicating effective cost management.
Product DevelopmentThe company is making material progress in areas such as yield and throughput for making affinity reagents, and advancements in immobilizing proteins and epitope detection.
Bears Say
Financial PerformanceManagement expects a 25% increase in operating expenses in FY24, signaling higher costs ahead.
Operational ChallengesNAUT pushed the launch timeline from 'mid 2024' to now '2025' citing challenges related to scale, reproducibility, stability.
Product LaunchNAUT delayed their platform launch to 2025, pushing potential revenue streams further into the future.
---
Ownership Overview
44.05% Insiders
3.95% Mutual Funds
4.94% Other Institutional Investors
47.06% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NAUT FAQ
What was Nautilus Biotechnolgy’s price range in the past 12 months?
Nautilus Biotechnolgy lowest stock price was $2.16 and its highest was $4.65 in the past 12 months.
What is Nautilus Biotechnolgy’s market cap?
Currently, no data Available
When is Nautilus Biotechnolgy’s upcoming earnings report date?
Nautilus Biotechnolgy’s upcoming earnings report date is Apr 30, 2024 which is in 6 days.
How were Nautilus Biotechnolgy’s earnings last quarter?
Nautilus Biotechnolgy released its earnings results on Feb 28, 2024. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.018.
Is Nautilus Biotechnolgy overvalued?
According to Wall Street analysts Nautilus Biotechnolgy’s price is currently Undervalued.
Does Nautilus Biotechnolgy pay dividends?
Nautilus Biotechnolgy does not currently pay dividends.
What is Nautilus Biotechnolgy’s EPS estimate?
Nautilus Biotechnolgy’s EPS estimate is -$0.16.
How many shares outstanding does Nautilus Biotechnolgy have?
Nautilus Biotechnolgy has 125,098,080 shares outstanding.
What happened to Nautilus Biotechnolgy’s price movement after its last earnings report?
Nautilus Biotechnolgy reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went down -4.762%.
Which hedge fund is a major shareholder of Nautilus Biotechnolgy?
Among the largest hedge funds holding Nautilus Biotechnolgy’s share is Perceptive Advisors LLC. It holds Nautilus Biotechnolgy’s shares valued at 38M.
---
Nautilus Biotechnolgy Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.88 (57.72% Upside)
$3.88 (57.72% Upside)
Hedge Fund Trend
Increased
By 3.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $140.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.3%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.21%
12-Months-Change
Fundamentals
Return on Equity
-21.95%
Trailing 12-Months
Asset Growth
-12.71%
Trailing 12-Months
Company Description
Nautilus Biotechnolgy
ARYA Sciences Acquisition Corp III is a blank check company.
---
NAUT Company Deck
---
NAUT Earnings Call
Q4 2024
0:00 / 0:00
---
NAUT Stock 12 Months Forecast
Average Price Target
$3.88
▲(57.72% Upside)
Technical Analysis
Best Analysts Covering NAUT
1 Year
1 Year Success Rate
0/2 ratings generated profit
1 Year Average Return
-10.75%
assigned a buy rating 2 months ago
Copying Daniel Brennan's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -10.75% per trade.
---